Reported med-tech deal value in the first seven months of 2025 remained sharply subdued, totaling just $657.44 million across ...

The amount of money raised through global biopharma IPOs in the first seven months of 2025 is at the lowest level since 2016, ...

The U.S. FDA has given a swift and full approval to Precigen Inc.’s gene therapy, Papzimeos (zopapogene imadenovec), for treating adults with recurrent respiratory papillomatosis (RRP), a rare and ...